Primary cellular immunodeficiencies

被引:76
作者
Buckley, RH [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA
关键词
severe combined immunodeficiency; T-cell activation defects; combined immunodeficiency; bone marrow transplantation; gene therapy;
D O I
10.1067/mai.2002.123617
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Genetic defects in T-cell function lead to susceptibility to infections or to other clinical problems that are more grave than those seen in disorders resulting in antibody deficiency alone. Those affected usually present during infancy with either common or opportunistic infections and rarely survive beyond infancy or childhood. The spectrum of T-cell defects ranges from the syndrome of severe combined immunodeficiency, in which T-cell function is absent, to combined immunodeficiency disorders in which there is some, but not adequate, T-cell function for a normal life span. Recent discoveries of the molecular causes of many of these defects have led to a new understanding of the flawed biology underlying the ever-growing number of defects. Most of these conditions could be diagnosed by means of screening for lymphopenia or for T-cell deficiency in cord blood at birth. Early recognition of those so afflicted is essential to the application of the most appropriate treatments for these conditions at a very early age. The latter treatments include both transplantation and gene therapy in addition to immunoglobulin replacement. Fully defining the molecular defects of such patients is also essential for genetic counseling of family members and prenatal diagnosis.
引用
收藏
页码:747 / 757
页数:11
相关论文
共 129 条
  • [51] Identification of WASP mutations, mutation hotspots and genotype-phenotype disparities in 24 patients with the Wiskott-Aldrich syndrome
    Greer, WL
    Shehabeldin, A
    Schulman, J
    Junker, A
    Siminovitch, KA
    [J]. HUMAN GENETICS, 1996, 98 (06) : 685 - 690
  • [52] The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis
    Haddad, E
    Zugaza, JL
    Louache, F
    Debili, N
    Crouin, C
    Schwarz, K
    Fischer, A
    Vainchenker, W
    Bertoglio, J
    [J]. BLOOD, 2001, 97 (01) : 33 - 38
  • [53] DNA-DEPENDENT PROTEIN-KINASE CATALYTIC SUBUNIT - A RELATIVE OF PHOSPHATIDYLINOSITOL 3-KINASE AND THE ATAXIA-TELANGIECTASIA GENE-PRODUCT
    HARTLEY, KO
    GELL, D
    SMITH, GCM
    ZHANG, H
    DIVECHA, N
    CONNELLY, MA
    ADMON, A
    LEESMILLER, SP
    ANDERSON, CW
    JACKSON, SP
    [J]. CELL, 1995, 82 (05) : 849 - 856
  • [54] Ataxia telangiectasia: Cell signaling, cell death and the cell cycle
    Heintz, N
    [J]. CURRENT OPINION IN NEUROLOGY, 1996, 9 (02) : 137 - 140
  • [55] Henwood J, 1996, J IMMUNOL, V156, P895
  • [56] PEG-ADA REPLACEMENT THERAPY FOR ADENOSINE-DEAMINASE DEFICIENCY - AN UPDATE AFTER 8.5 YEARS
    HERSHFIELD, MS
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 76 (03): : S228 - S232
  • [57] PEG-ADA - AN ALTERNATIVE TO HAPLOIDENTICAL BONE-MARROW TRANSPLANTATION AND AN ADJUNCT TO GENE-THERAPY FOR ADENOSINE-DEAMINASE DEFICIENCY
    HERSHFIELD, MS
    [J]. HUMAN MUTATION, 1995, 5 (02) : 107 - 112
  • [58] TREATMENT OF ADENOSINE-DEAMINASE DEFICIENCY WITH POLYETHYLENE-GLYCOL MODIFIED ADENOSINE-DEAMINASE
    HERSHFIELD, MS
    BUCKLEY, RH
    GREENBERG, ML
    MELTON, AL
    SCHIFF, R
    HATEM, C
    KURTZBERG, J
    MARKERT, ML
    KOBAYASHI, RH
    KOBAYASHI, AL
    ABUCHOWSKI, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (10) : 589 - 596
  • [59] Hirschhorn R, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P121
  • [60] HONG R, 1991, Immunodeficiency Reviews, V3, P1